Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia

Rebecca J. Watters, Todd E. Fox, Su Fern Tan, Sriram Shanmugavelandy, Jacob E. Choby, Kathleen Broeg, Jiangang (Jason) Liao, Mark Kester, Myles C. Cabot, Thomas P. Loughran, Xin Liu

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Natural killer (NK) cell leukemia is characterized by clonal expansion of CD3 - NK cells and comprises both chronic and aggressive forms. Currently no effective treatment exists, thus providing a need for identification of novel therapeutics. Lipidomic studies revealed a dysregulated sphingolipid metabolism as evidenced by decreased levels of overall ceramide species and increased levels of cerebrosides in leukemic NK cells, concomitant with increased glucosylceramide synthase (GCS) expression. GCS, a key enzyme of this pathway, neutralizes pro-apoptotic ceramide by transfer of a uridine diphosphate (UDP)-glucose. Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. Co-administration of C6-ceramide nanoliposomes and PPMP elicited an increase in endogenous long-chain ceramide species, which led to cellular apoptosis in a synergistic manner via the mitochondrial intrinsic cell death pathway in leukemic NK cells.

Original languageEnglish (US)
Pages (from-to)1288-1296
Number of pages9
JournalLeukemia and Lymphoma
Volume54
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

ceramide glucosyltransferase
Natural Killer Cells
Ceramides
Leukemia
Apoptosis
Cerebrosides
Uridine Diphosphate Glucose
Sphingolipids
Mitochondria
Cell Death
N-caproylsphingosine
Enzymes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Watters, Rebecca J. ; Fox, Todd E. ; Tan, Su Fern ; Shanmugavelandy, Sriram ; Choby, Jacob E. ; Broeg, Kathleen ; Liao, Jiangang (Jason) ; Kester, Mark ; Cabot, Myles C. ; Loughran, Thomas P. ; Liu, Xin. / Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 6. pp. 1288-1296.
@article{302eb16953ba40699fbc626bb66bc6c6,
title = "Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia",
abstract = "Natural killer (NK) cell leukemia is characterized by clonal expansion of CD3 - NK cells and comprises both chronic and aggressive forms. Currently no effective treatment exists, thus providing a need for identification of novel therapeutics. Lipidomic studies revealed a dysregulated sphingolipid metabolism as evidenced by decreased levels of overall ceramide species and increased levels of cerebrosides in leukemic NK cells, concomitant with increased glucosylceramide synthase (GCS) expression. GCS, a key enzyme of this pathway, neutralizes pro-apoptotic ceramide by transfer of a uridine diphosphate (UDP)-glucose. Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. Co-administration of C6-ceramide nanoliposomes and PPMP elicited an increase in endogenous long-chain ceramide species, which led to cellular apoptosis in a synergistic manner via the mitochondrial intrinsic cell death pathway in leukemic NK cells.",
author = "Watters, {Rebecca J.} and Fox, {Todd E.} and Tan, {Su Fern} and Sriram Shanmugavelandy and Choby, {Jacob E.} and Kathleen Broeg and Liao, {Jiangang (Jason)} and Mark Kester and Cabot, {Myles C.} and Loughran, {Thomas P.} and Xin Liu",
year = "2013",
month = "6",
day = "1",
doi = "10.3109/10428194.2012.752485",
language = "English (US)",
volume = "54",
pages = "1288--1296",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

Watters, RJ, Fox, TE, Tan, SF, Shanmugavelandy, S, Choby, JE, Broeg, K, Liao, JJ, Kester, M, Cabot, MC, Loughran, TP & Liu, X 2013, 'Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia', Leukemia and Lymphoma, vol. 54, no. 6, pp. 1288-1296. https://doi.org/10.3109/10428194.2012.752485

Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. / Watters, Rebecca J.; Fox, Todd E.; Tan, Su Fern; Shanmugavelandy, Sriram; Choby, Jacob E.; Broeg, Kathleen; Liao, Jiangang (Jason); Kester, Mark; Cabot, Myles C.; Loughran, Thomas P.; Liu, Xin.

In: Leukemia and Lymphoma, Vol. 54, No. 6, 01.06.2013, p. 1288-1296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia

AU - Watters, Rebecca J.

AU - Fox, Todd E.

AU - Tan, Su Fern

AU - Shanmugavelandy, Sriram

AU - Choby, Jacob E.

AU - Broeg, Kathleen

AU - Liao, Jiangang (Jason)

AU - Kester, Mark

AU - Cabot, Myles C.

AU - Loughran, Thomas P.

AU - Liu, Xin

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Natural killer (NK) cell leukemia is characterized by clonal expansion of CD3 - NK cells and comprises both chronic and aggressive forms. Currently no effective treatment exists, thus providing a need for identification of novel therapeutics. Lipidomic studies revealed a dysregulated sphingolipid metabolism as evidenced by decreased levels of overall ceramide species and increased levels of cerebrosides in leukemic NK cells, concomitant with increased glucosylceramide synthase (GCS) expression. GCS, a key enzyme of this pathway, neutralizes pro-apoptotic ceramide by transfer of a uridine diphosphate (UDP)-glucose. Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. Co-administration of C6-ceramide nanoliposomes and PPMP elicited an increase in endogenous long-chain ceramide species, which led to cellular apoptosis in a synergistic manner via the mitochondrial intrinsic cell death pathway in leukemic NK cells.

AB - Natural killer (NK) cell leukemia is characterized by clonal expansion of CD3 - NK cells and comprises both chronic and aggressive forms. Currently no effective treatment exists, thus providing a need for identification of novel therapeutics. Lipidomic studies revealed a dysregulated sphingolipid metabolism as evidenced by decreased levels of overall ceramide species and increased levels of cerebrosides in leukemic NK cells, concomitant with increased glucosylceramide synthase (GCS) expression. GCS, a key enzyme of this pathway, neutralizes pro-apoptotic ceramide by transfer of a uridine diphosphate (UDP)-glucose. Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. Co-administration of C6-ceramide nanoliposomes and PPMP elicited an increase in endogenous long-chain ceramide species, which led to cellular apoptosis in a synergistic manner via the mitochondrial intrinsic cell death pathway in leukemic NK cells.

UR - http://www.scopus.com/inward/record.url?scp=84877734277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877734277&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.752485

DO - 10.3109/10428194.2012.752485

M3 - Article

VL - 54

SP - 1288

EP - 1296

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -